Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Pluvicto
Pluvicto is a radioactive medicine used to target and treat advanced prostate cancer that has spread and no longer responds to hormone therapy.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Lutetium (177lu) Vipivotide Tetraxetan
Lutetium (177Lu) vipivotide tetraxetan is a targeted radioactive treatment that delivers radiation directly to prostate cancer cells with a protein called PSMA.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitaetsklinikum Essen AöR
Department of Urology
Essen, Germany
Sponsor: Universitaetsklinikum Essen AöR
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.